Recombinant Anti-FGFR1 (phospho Y653) antibody [EPR843(N)] (ab173305)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR843(N)] to FGFR1 (phospho Y653)
- Suitable for: WB, IHC-P
- Reacts with: Mouse, Human
Related conjugates and formulations
Overview
-
Product name
Anti-FGFR1 (phospho Y653) antibody [EPR843(N)]
See all FGFR1 primary antibodies -
Description
Rabbit monoclonal [EPR843(N)] to FGFR1 (phospho Y653) -
Host species
Rabbit -
Specificity
Stimulation may be required to allow detection of the phosphorylated protein. Please see images below for recommended treatment conditions and positive controls.
-
Tested applications
Suitable for: WB, IHC-Pmore details
Unsuitable for: Flow Cyt,ICC or IP -
Species reactivity
Reacts with: Mouse, Human
Predicted to work with: Rat -
Immunogen
-
Positive control
- WB: NIH/3T3 cell lysate treated with pervanadate. IHC-P: Human glioma tissue.
-
General notes
This antibody was developed as part of a collaboration between Epitomics and Ira Daar at the National Cancer Institute, NIH.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Constituents: 0.35% Sodium citrate, 0.17% Sodium chloride, 0.03% EDTA, 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR843(N) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab173305 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/5000. Predicted molecular weight: 92 kDa.
|
|
IHC-P | (1) |
1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
Notes |
---|
WB
1/1000 - 1/5000. Predicted molecular weight: 92 kDa. |
IHC-P
1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Target
-
Function
Receptor for basic fibroblast growth factor. Receptor for FGF23 in the presence of KL (By similarity). A shorter form of the receptor could be a receptor for FGF1 (aFGF). -
Tissue specificity
Detected in astrocytoma, neuroblastoma and adrenal cortex cell lines. Some isoforms are detected in foreskin fibroblast cell lines, however isoform 17, isoform 18 and isoform 19 are not detected in these cells. -
Involvement in disease
Defects in FGFR1 are a cause of Pfeiffer syndrome (PS) [MIM:101600]; also known as acrocephalosyndactyly type V (ACS5). PS is characterized by craniosynostosis (premature fusion of the skull sutures) with deviation and enlargement of the thumbs and great toes, brachymesophalangy, with phalangeal ankylosis and a varying degree of soft tissue syndactyly.
Defects in FGFR1 are a cause of idiopathic hypogonadotropic hypogonadism (IHH) [MIM:146110]. IHH is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function.
Defects in FGFR1 are the cause of Kallmann syndrome type 2 (KAL2) [MIM:147950]; also known as hypogonadotropic hypogonadism and anosmia. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In some cases, midline cranial anomalies (cleft lip/palate and imperfect fusion) are present and anosmia may be absent or inconspicuous.
Defects in FGFR1 are the cause of osteoglophonic dysplasia (OGD) [MIM:166250]; also known as osteoglophonic dwarfism. OGD is characterized by craniosynostosis, prominent supraorbital ridge, and depressed nasal bridge, as well as by rhizomelic dwarfism and nonossifying bone lesions. Inheritance is autosomal dominant.
Defects in FGFR1 are the cause of trigonocephaly non-syndromic (TRICEPH) [MIM:190440]; also known as metopic craniosynostosis. The term trigonocephaly describes the typical keel-shaped deformation of the forehead resulting from premature fusion of the frontal suture. Trigonocephaly may occur also as a part of a syndrome.
Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell leukemia lymphoma syndrome (SCLL). Translocation t(8;13)(p11;q12) with ZMYM2. SCLL usually presents as lymphoblastic lymphoma in association with a myeloproliferative disorder, often accompanied by pronounced peripheral eosinophilia and/or prominent eosinophilic infiltrates in the affected bone marrow.
Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(6;8)(q27;p11) with FGFR1OP. Insertion ins(12;8)(p11;p11p22) with FGFR1OP2. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion proteins FGFR1OP2-FGFR1, FGFR1OP-FGFR1 or FGFR1-FGFR1OP may exhibit constitutive kinase activity and be responsible for the transforming activity.
Note=A chromosomal aberration involving FGFR1 may be a cause of stem cell myeloproliferative disorder (MPD). Translocation t(8;9)(p12;q33) with CEP110. MPD is characterized by myeloid hyperplasia, eosinophilia and T-cell or B-cell lymphoblastic lymphoma. In general it progresses to acute myeloid leukemia. The fusion protein CEP110-FGFR1 is found in the cytoplasm, exhibits constitutive kinase activity and may be responsible for the transforming activity. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.
Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
Post-translational
modificationsBinding of FGF1 and heparin promotes autophosphorylation on tyrosine residues and activation of the receptor. -
Cellular localization
Membrane. Nucleus. Cytoplasm. Cytoplasmic vesicle - Information by UniProt
-
Database links
- Entrez Gene: 2260 Human
- Entrez Gene: 14182 Mouse
- Entrez Gene: 79114 Rat
- Omim: 136350 Human
- SwissProt: P11362 Human
- SwissProt: P16092 Mouse
- SwissProt: Q04589 Rat
- Unigene: 264887 Human
see all -
Alternative names
- Basic fibroblast growth factor receptor 1 antibody
- bFGF-R-1 antibody
- BFGFR antibody
see all
Images
-
All lanes : Anti-FGFR1 (phospho Y653) antibody [EPR843(N)] (ab173305) at 1/1000 dilution
Lane 1 : Untreated NIH/3T3 (Mouse embryo fibroblast cell line) cell lysate
Lane 2 : NIH/3T3 (Mouse embryo fibroblast cell line) cell lysate treated with pervanadate
Lysates/proteins at 10 µg per lane.
Predicted band size: 92 kDa -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-FGFR1 (phospho Y653) antibody [EPR843(N)] (ab173305)
Immunohistochemical analysis of paraffin-embedded human glioma tissue labeling FGFR1 (phospho Y653) with ab173305 at 1/50 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Protocols
Datasheets and documents
-
Datasheet download
References (7)
ab173305 has been referenced in 7 publications.
- Homer-Bouthiette C et al. Gait disturbances and muscle dysfunction in fibroblast growth factor 2 knockout mice. Sci Rep 11:11005 (2021). PubMed: 34040128
- Bhattacharyya S et al. Acidic fibroblast growth factor underlies microenvironmental regulation of MYC in pancreatic cancer. J Exp Med 217:N/A (2020). PubMed: 32434218
- Li L et al. Brivanib, a multitargeted small-molecule tyrosine kinase inhibitor, suppresses laser-induced CNV in a mouse model of neovascular AMD. J Cell Physiol 235:1259-1273 (2020). PubMed: 31270802
- Zhen C et al. MicroRNA-652 inhibits the biological characteristics of esophageal squamous cell carcinoma by directly targeting fibroblast growth factor receptor 1. Exp Ther Med 18:4473-4480 (2019). PubMed: 31777550
- Liu J et al. Peptide-based NTA(Ni)-nanodiscs for studying membrane enhanced FGFR1 kinase activities. PeerJ 7:e7234 (2019). PubMed: 31372315
- Kang J et al. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment. Sci Rep 9:8726 (2019). PubMed: 31217507
- Seo HR et al. Intrinsic FGF2 and FGF5 promotes angiogenesis of human aortic endothelial cells in 3D microfluidic angiogenesis system. Sci Rep 6:28832 (2016). WB ; Human . PubMed: 27357248